Source: Annual Congress 2002 - Fungal and nocardial infections, and infections in the immunocompromised and elderly
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wiersbitzky, P. Abel, C. Greve, C. Warnke, N. Bordihn (Greifswald, Germany). Immunomodulating therapy and the risk of severe pneumonia. Eur Respir J 2002; 20: Suppl. 38, 2186

Member's Comments

No comment yet.

Related content which might interest you: Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Immunostimulating therapy in treatment of Community-acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Efferent therapy in complex treatment of community-acquired pneumonia in patients with immunosuppression Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Anti-inflammatory therapy in rehabilitation program in patients with pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 517s Year: 2004 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Telithromycin is effective in the treatment of patients with acute exacerbations of chronic bronchitis and risk factors for morbidity Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Antibacterial therapy of community-acquired pneumonia (CAP) at patients with cardiovascular diseases (CVD) Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Intrahospital cardiovascular complications in severe community-acquired pneumonia Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017